A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection

Published on
Journal: Molecular Therapy
[저자] Stephen Boulton, Joanna Poutou, Rida Gill, Nouf Alluqmani, Xiaohong He, Ragunath Singaravelu, Mathieu J.F. Crupi, Julia Petryk, Bradley Austin, Leonard Angka, Zaid Taha, Iris Teo, Siddarth Singh, Rameen Jamil, Ricardo Marius, Nikolas Martin, Taylor Jamieson, Taha Azad, Jean-Simon Diallo, Carolina S. Ilkow, John C. Bell
[Category] update2024,
PMC URL    Pubmed URL    DOI URL    [DOI] 10.1016/j.omtm.2023.101110    
[Article Type] Original Article
[Source] PMC

The study describes a second-generation COVID-19 vaccine developed with a live-attenuated vaccinia virus vector encoded with immunodominant T cell and B cell antigens. The design generates robust, long-lasting protective immunity while reducing the risk of vaccine resistance through a combination of epitopes that are highly conserved among SARS-CoV-2 variants.

All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, Vaccine, spike, T cell, nucleocapsid, vaccinia virus, poly-epitope,